本报记者 方凌晨 汇添富香港优势精选混合（QDII）A以143.24%的年内净值增长率暂居榜首。从最新披露情况来看，该基金在今年二季度 对组合的重仓方向、结构、个股调整不多，仍继续看好创新药方向。截至今年二季度末，汇添富香港优势精选混合（QDII）股 票投资仓位达92.65%，其重仓股包括等。 此外，除了长城医药产业精选混合发起式、中银港股通医药混合发起等医药主题基金，诺安精选价值混合、中航优选领航 混合发起、嘉实互融精选股票等"翻倍基"也选择重仓创新药。诺安精选价值混合基金管理人表示，今年二季度创新药板块主要 演绎了"大额对外授权预期"这一逻辑，符合该基金"寻找与时代相契合的超级大单品"的选股策略。 亮眼的业绩表现也吸引了市场资金持续流入，部分"翻倍基"规模增长显著。截至8月14日，广发中证香港创新药（QDII- ETF）、汇添富国证港股通创新药ETF的上市基金规模已达190.43亿元、149.94亿元。为了保证基金的稳定运作和保护基金份额 持有人的利益，部分基金则已选择限购。例如汇添富香港优势精选混合（QDII）已在7月份下旬暂停申购。 汇添富香港优势精选混合（QDII）基金经理张韡认为，目前市场对创新药 ...

Group 1 - The core viewpoint is that actively managed equity funds are regaining attention and performance after years of underperformance, with significant returns observed in 2023 [2][3] - As of August 6, 2023, the Dongcai Ordinary Stock Fund Index and the Mixed Equity Fund Index both exceeded a 16% increase, outperforming passive index funds and fixed-income funds [3] - Nearly 10 actively managed equity funds have doubled their net value this year, with notable funds like Huazhang Medical Industry Selected Mixed Fund seeing a 130% increase in net value [3][4] Group 2 - Despite some actively managed funds experiencing significant inflows, the overall scale of these funds has declined, with a nearly 10 billion yuan drop in total scale in Q2 2023 [4] - The market's rapid changes and sector rotations have increased investment difficulty, with industry rotation cycles shortening to about two months [5][6] - Fund managers are facing higher demands for timely and precise adjustments to their portfolios due to frequent shifts in market sentiment and investment noise [5][6] Group 3 - The investment strategy has shifted from relying on broad market trends to focusing on individual stock selection, with a notable decline in the concentration of holdings in top sectors and stocks [8][9] - Fund managers are increasingly looking for opportunities in smaller, innovative companies, particularly in the pharmaceutical sector, which are on the verge of value reassessment [9][10] - The industry is emphasizing the importance of enhancing research capabilities and establishing a robust investment research framework to adapt to the evolving market landscape [10]

Core Viewpoint - The performance of actively managed equity funds in the A-share market has rebounded significantly, with over 90% of products achieving net value growth this year, indicating a strong wealth effect and potential for a virtuous cycle in the market [1][4]. Group 1: Fund Performance - As of August 7, 2023, 4,598 actively managed equity funds were tracked, with 4,347 (94.54%) achieving net value growth this year [2]. - Notably, 127 funds recorded a net value growth rate exceeding 50%, and 6 funds surpassed 100% [2]. - A total of 1,126 funds reached new net value highs since their inception this year [2]. Group 2: Key Investment Themes - Innovation in pharmaceuticals and technology are identified as the two main drivers of net value growth for actively managed equity funds [2]. - The Changcheng Medical Industry Selected Mixed Fund led with a 129.97% net value growth rate, focusing heavily on innovative pharmaceuticals [2][3]. - The Yongying Technology Smart Selection Mixed Fund achieved a 91.23% net value growth rate, concentrating on the global cloud computing industry [3]. Group 3: Market Sentiment and Fund Flows - The recovery in actively managed equity fund performance is expected to enhance investor confidence, leading to increased fund subscriptions and market stability [4][5]. - The Yongying Advanced Manufacturing Smart Selection Mixed Fund's size grew from 1.762 billion to 13.845 billion yuan, while the Penghua Carbon Neutrality Theme Mixed Fund expanded from 1.035 billion to 10.863 billion yuan this year [4]. - Fund sales personnel reported a noticeable increase in investor interest and purchase intentions, with many public institutions accelerating the issuance of new funds, particularly in equity [5].

Group 1 - The core viewpoint of the articles indicates that several high-performing public funds are actively adjusting their portfolios to capture structural opportunities in the market, particularly focusing on the technology and pharmaceutical sectors, reflecting an optimistic outlook for the second half of the year [1][3] - As of July 16, among the disclosed second-quarter reports, many top-performing funds have increased their stock investment ratios, with notable examples including the Changcheng Pharmaceutical Industry Selected Mixed Fund, which raised its stock investment ratio from 72.48% to 75.89%, and the Tongtai Industrial Upgrade Mixed A Fund, which increased its stock investment ratio from 1.62% to 90.16% [1] - The holding structure shows that technology and pharmaceuticals are the main targets for fund managers' adjustments, with funds like Yongying Technology Smart Mixed A shifting focus to global cloud computing and increasing positions in leading companies in optical communication [1][3] Group 2 - Analysts express confidence in the overall performance of the equity market, with many top funds maintaining high positions based on positive assessments of relevant sectors, particularly in structural market conditions where active equity funds can leverage their stock-picking advantages [3] - Fund managers are optimistic about the third quarter, with specific focus areas including the development of innovative drugs in overseas licensing and domestic sales, as well as investment opportunities in cutting-edge models and emerging applications in the technology sector [3] - The proactive adjustments and increased allocations by high-performing funds in the second quarter reflect a long-term positive outlook on high-growth sectors like technology and pharmaceuticals, signaling potential structural opportunities in the equity market for the latter half of the year [3]

Group 1 - The core viewpoint of the article highlights that several high-performing public funds have increased their equity asset positions in Q2, focusing on structural opportunities in the technology and pharmaceutical sectors [1][2]. - As of July 16, multiple top-performing funds have reported significant increases in their equity allocations, with the Longcheng Pharmaceutical Industry Selected Mixed Fund achieving a net value growth rate of 75.18% in the first half of the year, alongside a 9.3-fold increase in asset scale [2][3]. - The stock investment ratio of the Longcheng Pharmaceutical Fund rose from 72.48% at the end of Q1 to 75.89% at the end of Q2, indicating a strategic shift towards higher equity exposure [2]. Group 2 - Fund managers have concentrated their adjustments towards the technology and pharmaceutical sectors, with notable shifts in holdings among top stocks, such as the transition of Yongying Technology's focus from "cloud computing and data centers" to the "global cloud computing industry" [3][4]. - Analysts suggest that in a structural market, actively managed equity funds can leverage stock selection advantages to achieve excess returns, particularly in high-growth sectors like artificial intelligence and robotics [4]. - Looking ahead, fund managers maintain an optimistic outlook for Q3, with expectations for innovation in pharmaceuticals and advancements in cloud computing, indicating a proactive investment strategy [4][5].

Core Insights - Multiple equity funds have increased their stock positions in Q2 2025, with a focus on sectors such as robotics, fintech, and pharmaceuticals [1][4][5] Fund Performance and Strategy - As of the end of Q2, several funds reported stock positions exceeding 80%, with notable increases in positions for funds like Tongtai Yuanjian Mixed, which rose from 78.65% to 85.74%, and Tongtai Industrial Upgrade Mixed, which jumped from 1.62% to 90.16% [2][3] - Longcheng Fund's pharmaceutical-themed funds achieved significant net value growth, with Longcheng Pharmaceutical Industry Selected Mixed A and C shares recording growth rates of 35.86% and 35.72% respectively [3] Sector Focus - The investment focus varies among funds, with some shifting their portfolios. For instance, Tongtai Industrial Upgrade Mixed transitioned from banking stocks to robotics, while Tongtai Financial Selected Stock maintained a focus on long-term investments in the financial sector [3] - The investment strategy of Debang New Return Flexible Configuration Mixed involves a mix of fixed income and equity assets, with a focus on banks, white goods, public environmental protection, and gold [3] Future Investment Opportunities - Fund managers are optimistic about investment opportunities in robotics, pharmaceuticals, and fintech. The robotics sector is expected to see significant growth driven by increased orders from leading manufacturers and advancements in large model technology [4] - In the pharmaceutical sector, there is anticipation for the growth of innovative drugs, particularly in overseas licensing and domestic sales, with expectations tied to quarterly reports and negotiations with medical insurance [5][6] - The financial sector is viewed as having potential for performance elasticity, especially if the A-share market rebounds, which could benefit brokerage, asset management, and proprietary trading businesses [6]

Core Insights - The active equity funds have shown a dramatic contrast in performance amidst rising capital market volatility, with the first "doubling fund" emerging in the year, igniting market enthusiasm, while new fund issuance remains relatively subdued [1][3] - As of June 13, the "Huitianfu Hong Kong Advantage Selected Mixed A/C" fund achieved a year-to-date return exceeding 100%, becoming a market highlight, while 16 active equity funds have returns over 70% [3][4] - Despite strong performance from some funds, the new issuance of active equity funds has been lackluster, with a total of 299.16 billion yuan raised in new funds this year, accounting for only 6.56% of the total public offering new issuance [5][6] Fund Performance - The first "doubling fund" appeared in the active equity market, with the "Huitianfu Hong Kong Advantage Selected Mixed" fund showing a year-to-date increase of over 100% [3] - Other notable funds include "Changcheng Medical Industry Selected Mixed" with over 87% return and "Yongying Medical Innovation Smart Selection" with over 79% return [3] - The overall average return for active equity funds this year is 2.87%, with a significant disparity of 132.35 percentage points between the best and worst performers [3][4] Fund Issuance - A total of 89 new active equity funds were established this year, with the largest fund being "Oriental Red Core Value Mixed" at 19.91 billion yuan [5][6] - 32 active equity funds had issuance sizes below 1 billion yuan, indicating a trend towards smaller fund launches [5] - The failure of the "Shenwan Lingshin Vision Growth Mixed" fund to meet fundraising conditions highlights challenges in the current market environment [6] Market Outlook - Analysts suggest that the key to breaking the current stagnation in new fund issuance lies in enhancing asset allocation capabilities and improving net value performance [7][8] - The recent reforms in public funds emphasize the alignment of fund company income with investor returns, which may enhance the attractiveness of existing products and instill confidence in new offerings [8] - Future issuance of active equity funds may improve as market conditions stabilize and investor confidence returns, with a focus on optimizing product design and enhancing service quality [8][9]